Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
J Pathol Clin Res. 2018 Oct;4(4):213-226. doi: 10.1002/cjp2.111. Epub 2018 Sep 18.
While a variety of human papillomavirus (HPV) tests and surrogate markers are available, currently there is no consensus on the best detection method(s) that should be used to identify HPV-related oropharyngeal squamous cell carcinomas and serve as a standard test (or tests) for routine diagnostic use. As we begin to consider using the results of HPV testing for clinical purposes beyond simple prognostication, such as making decisions on treatment dose or duration or for targeted therapies that may be highly dependent on viral-mediated pathways, we need to be more rigorous in assessing and ensuring the performance of the test (or tests) used. Here we provide an overview of the platforms and technologies, including the strengths and limitations of each test, and discuss what steps are needed to generate confidence in their performance for use in clinical practice.
虽然有多种人乳头瘤病毒（HPV）检测和替代标志物可用，但目前对于应使用哪种最佳检测方法来识别 HPV 相关的口咽鳞状细胞癌并作为常规诊断用途的标准检测（或检测）尚无共识。当我们开始考虑将 HPV 检测结果用于临床目的，例如不仅仅是预测预后，而是用于决定治疗剂量或持续时间，或用于可能高度依赖病毒介导途径的靶向治疗时，我们需要更严格地评估和确保所使用的检测（或检测）的性能。在这里，我们提供了平台和技术的概述，包括每个测试的优缺点，并讨论了需要采取哪些步骤来建立对其在临床实践中使用的性能的信心。
